OPRM1 and COVID-19: Hence, it is possible that the presence of post-COVID-19 pain symptomatology can be associated with DNA methylation changes in genes associated with inflammation, (e.g., OPRM1 or TRPA1) rather than in those genes associated with COVID-19 susceptibility (e.g., ACE2 promoter) such as those described in our study.